Makoto Nishio Selected Research

Makoto Nishio Research Topics

Disease

158	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024 - 04/2005
62	Neoplasms (Cancer) 04/2024 - 02/2009
31	Lung Neoplasms (Lung Cancer) 02/2024 - 04/2008
22	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 02/2024 - 03/2008
22	Disease Progression 01/2024 - 10/2013
12	Neoplasm Metastasis (Metastasis) 01/2023 - 04/2008
11	Brain Neoplasms (Brain Tumor) 03/2024 - 01/2016
11	Diarrhea 01/2023 - 04/2005
10	Neutropenia 10/2020 - 04/2005
9	Febrile Neutropenia 01/2020 - 01/2011
8	Adenocarcinoma of Lung 01/2024 - 02/2009
6	Exanthema (Rash) 03/2024 - 10/2014
6	Hypertension (High Blood Pressure) 12/2022 - 10/2014
6	Nausea 04/2021 - 04/2011
6	Anorexia 01/2020 - 04/2011
5	Thrombocytopenia (Thrombopenia) 01/2017 - 01/2014
4	Adenocarcinoma 01/2023 - 04/2011
3	Thymoma (Thymic Carcinoma) 01/2022 - 01/2019
2	Central Nervous System Diseases (CNS Diseases) 04/2024 - 01/2018
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2024 - 01/2021
2	Carcinoma (Carcinomatosis) 02/2024 - 10/2017
2	Colorectal Neoplasms (Colorectal Cancer) 10/2020 - 10/2016
2	Vomiting 10/2020 - 05/2018
2	Fatigue 10/2020 - 10/2016
2	Dermatitis 05/2020 - 12/2019
2	Radiation Pneumonitis 01/2020 - 01/2014
2	Meningeal Carcinomatosis 01/2020 - 01/2017
2	Pneumonia (Pneumonitis) 12/2019 - 08/2016
2	Hemorrhage 10/2019 - 01/2018
2	Adrenal Insufficiency (Adrenal Gland Hypofunction) 01/2019 - 01/2017

Drug/Important Bio-Agent (IBA)

50	Tyrosine Kinase InhibitorsIBA 02/2024 - 06/2007
38	ErbB Receptors (EGF Receptor)IBA 01/2024 - 06/2007
25	Anaplastic Lymphoma KinaseIBA 11/2023 - 08/2013
22	Erlotinib Hydrochloride (CP 358,774)FDA Link 08/2023 - 09/2013
21	PlatinumIBA 04/2024 - 09/2006
18	alectinibIBA 04/2024 - 06/2013
18	CrizotinibIBA 03/2024 - 06/2013
18	NivolumabIBA 01/2024 - 01/2016
16	B7-H1 AntigenIBA 10/2023 - 01/2017
16	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 08/2005
15	Carboplatin (JM8)FDA LinkGeneric 01/2023 - 01/2011
14	ceritinibIBA 12/2022 - 06/2014
13	Gefitinib (Iressa)FDA Link 01/2023 - 05/2005
12	Bevacizumab (Avastin)FDA Link 06/2023 - 09/2014
11	Biomarkers (Surrogate Marker)IBA 06/2023 - 09/2010
10	osimertinibIBA 01/2024 - 12/2016
10	Docetaxel (Taxotere)FDA Link 10/2023 - 08/2005
10	Pemetrexed (MTA)FDA Link 01/2022 - 08/2013
9	Alanine Transaminase (SGPT)IBA 03/2024 - 01/2011
9	Paclitaxel (Taxol)FDA LinkGeneric 01/2023 - 04/2011
8	lorlatinibIBA 03/2024 - 01/2019
8	Etoposide (VP 16)FDA LinkGeneric 02/2024 - 01/2014
8	Immune Checkpoint InhibitorsIBA 01/2024 - 01/2016
8	atezolizumabIBA 01/2023 - 12/2018
7	pembrolizumabIBA 03/2024 - 03/2019
7	IpilimumabIBA 10/2023 - 01/2019
7	Irinotecan (Camptosar)FDA LinkGeneric 08/2016 - 04/2005
6	brigatinibIBA 09/2023 - 01/2020
6	RamucirumabIBA 08/2023 - 01/2016
6	Gemcitabine FDA Link 06/2019 - 04/2005
5	Phosphotransferases (Kinase)IBA 02/2024 - 07/2014
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2023 - 05/2005
5	Monoclonal AntibodiesIBA 05/2019 - 06/2015
4	AntibodiesIBA 02/2024 - 01/2020
4	Circulating Tumor DNAIBA 11/2023 - 10/2019
4	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2023 - 01/2019
4	amrubicinIBA 01/2023 - 04/2014
4	Proteins (Proteins, Gene)FDA Link 05/2022 - 01/2016
3	Cell-Free Nucleic AcidsIBA 08/2023 - 06/2021
3	Vinorelbine (Navelbine)FDA LinkGeneric 01/2022 - 01/2018
3	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2022 - 09/2010
3	dacomitinibIBA 01/2022 - 12/2014
3	LigandsIBA 09/2020 - 01/2019
2	Tumor Biomarkers (Tumor Markers)IBA 02/2024 - 12/2011
2	SynaptophysinIBA 02/2024 - 01/2020
2	Chromogranin AIBA 02/2024 - 01/2020
2	Creatine Kinase (Creatine Phosphokinase)IBA 12/2022 - 12/2022
2	selpercatinibIBA 06/2022 - 01/2020
2	capmatinibIBA 01/2022 - 01/2020
2	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 09/2013
2	CreatinineIBA 04/2021 - 01/2019
2	entrectinibIBA 01/2021 - 01/2019
2	vandetanib (ZD6474)IBA 01/2021 - 01/2017
2	Immunoglobulin G (IgG)IBA 01/2021 - 01/2016
2	AntiemeticsIBA 10/2020 - 05/2018
2	Antineoplastic Agents (Antineoplastics)IBA 01/2020 - 01/2019
2	Transcription Factors (Transcription Factor)IBA 01/2020 - 12/2015
2	TAS-121IBA 12/2019 - 01/2019
2	Warfarin (Coumadin)FDA LinkGeneric 10/2019 - 04/2011
2	necitumumabIBA 06/2019 - 01/2019
2	Histone Deacetylase InhibitorsIBA 01/2019 - 01/2017
2	onartuzumabIBA 01/2019 - 06/2015
2	naquotinibIBA 09/2018 - 08/2018

Therapy/Procedure

52	Drug Therapy (Chemotherapy) 04/2024 - 04/2005
43	Therapeutics 02/2024 - 01/2012
7	Chemoradiotherapy 01/2021 - 05/2011
6	Radiotherapy 01/2020 - 07/2013
5	Immunotherapy 01/2023 - 01/2017
5	Aftercare (After-Treatment) 01/2022 - 06/2007
3	Combination Drug Therapy (Combination Chemotherapy) 08/2016 - 04/2005